InterMune PT Raised to $12.00 at Goldman Sachs Group Inc. (ITMN)
Analysts at Goldman Sachs Group Inc. boosted their price target on shares of InterMune (NASDAQ:ITMN) from $11.00 to $12.00 in a research report issued to clients and investors on Wednesday, AnalystRatings.Net reports. Goldman Sachs Group Inc.’s target price suggests a potential downside of 20.58% from the stock’s previous close.
InterMune (NASDAQ:ITMN) traded up 0.07% during mid-day trading on Wednesday, hitting $15.11. The stock had a trading volume of 826,905 shares. InterMune has a 52 week low of $7.80 and a 52 week high of $16.00. The stock’s 50-day moving average is $14.84 and its 200-day moving average is $11.22. The company’s market cap is $1.238 billion.
InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Wednesday, July 24th. The company reported ($0.77) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.70) by $0.07. The company had revenue of $14.40 million for the quarter, compared to the consensus estimate of $12.95 million. During the same quarter in the previous year, the company posted $0.01 earnings per share. The company’s revenue for the quarter was up 160.0% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.85 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ITMN. Analysts at JMP Securities raised their price target on shares of InterMune (NASDAQ:ITMN) from $15.00 to $18.00 in a research note to investors on Thursday, July 25th. They now have a “market outperform” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of InterMune (NASDAQ:ITMN) from $13.00 to $17.00 in a research note to investors on Thursday, July 25th. They now have a “buy” rating on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of InterMune (NASDAQ:ITMN) in a research note to investors on Thursday, July 25th. They now have a $18.00 price target on the stock, up previously from $17.00.
Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.75.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.